Haploidentical Hematopoietic Stem Cell Transplantation in Thalassemia.
Haploidentical transplant
post-cyclophosphamide (CPM)
thalassemia
Journal
Hemoglobin
ISSN: 1532-432X
Titre abrégé: Hemoglobin
Pays: England
ID NLM: 7705865
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
pubmed:
4
8
2022
medline:
13
8
2022
entrez:
3
8
2022
Statut:
ppublish
Résumé
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only established treatment that is potentially curative, but it is limited by the availability of donors and the medical condition of the patient. To expand the donor pool to include haploidentical related donors, we introduced a program consisting of a pharmacologic pre transplant immune suppression phase (PTIS) and two courses of dexamethasone (DXM) and fludarabine (FLU) followed by pre transplant conditioning with intravenous FLU busulfan (BU) and post transplant graft-
Identifiants
pubmed: 35920292
doi: 10.1080/03630269.2022.2059671
doi:
Substances chimiques
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM